Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?

Bio-Techne (TECH) is set to release its fourth-quarter fiscal 2026 results on August 5th, with analysts projecting revenues of $317.2 million and EPS of 52 cents. The company recently agreed to be acquired by Merck KGaA for approximately $11.3 billion. Key factors influencing its performance include the potential recovery of its protein sciences portfolio and growth in diagnostic and spatial technology products.